Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study

Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study

Hongjie Cai,1 Song Chen,2 Zhiqiang Wu,1 Fan Wang,1 Shuangyan Tang,1 Ludan Chen,1 Wenbo Guo1 1Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510062, People’s Republic of China; 2Department of Minimally Invasive Interventional Therapy, Sun Y...

Full description

Bibliographic Details
Main Authors:	Cai H, Chen S, Wu Z, Wang F, Tang S, Chen L, Guo W
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-02-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	immune checkpoint inhibitors tyrosine kine inhibitors local therapy systemic therapy large unresectable hepatocellular carcinoma.
Online Access:	https://www.dovepress.com/atezolizumab-plus-bevacizumab-combined-with-transarterial-embolization-peer-reviewed-fulltext-article-JHC

Similar Items

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
by: Shigeki Yano, et al.
Published: (2023-11-01)

Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
by: Deng L, et al.
Published: (2024-01-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
by: Nan Jiang, et al.
Published: (2023-07-01)

Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
by: Masayuki Okuno, et al.
Published: (2023-08-01)

Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials
by: Han Dong, et al.
Published: (2023-06-01)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
by: Xingzhi Li, et al.
Published: (2023-01-01)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
by: Xue-Gang Yang, et al.
Published: (2022-07-01)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
by: Naoto Saito, et al.
Published: (2022-07-01)

Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization
by: Chengjian He, et al.
Published: (2022-06-01)

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab
by: Yun Beom Sang, et al.
Published: (2024-02-01)

Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective studyResearch in context
by: Xu-Kun Wu, et al.
Published: (2024-01-01)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
by: Zijian Yang, et al.
Published: (2023-01-01)

Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report
by: Yoshifumi Hidaka, et al.
Published: (2022-07-01)

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
by: Wu SJ, et al.
Published: (2023-06-01)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01)

Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
by: Peng Guo, et al.
Published: (2022-10-01)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
by: Jinpeng Li, et al.
Published: (2023-07-01)

A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
by: Soon Kyu Lee, et al.
Published: (2023-09-01)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
by: Wu JY, et al.
Published: (2021-10-01)

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Weiwei Li, et al.
Published: (2022-08-01)

Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
by: Xin Zhou, et al.
Published: (2021-10-01)

Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
by: Hao Li, et al.
Published: (2023-11-01)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
by: Carla Fernanda Nava, et al.
Published: (2019-10-01)

Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: a retrospective controlled study
by: Song Chen, et al.
Published: (2023-11-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01)

A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
by: Baojiang Liu, et al.
Published: (2023-08-01)

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
by: Alessandro Rizzo, et al.
Published: (2021-12-01)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
by: Pei-Chang Lee, et al.
Published: (2020-01-01)

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
by: Hideaki Bando, et al.
Published: (2020-04-01)

Conversion surgery following gemcitabine plus cisplatin therapy for initially unresectable gallbladder cancer with peritoneal carcinomatosis: a case report
by: Yusuke Wakasa, et al.
Published: (2022-03-01)

A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
by: Zhi-Mei Huang, et al.
Published: (2024-01-01)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
by: Han Seul Kim, et al.
Published: (2023-08-01)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024-03-01)

From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies
by: Chen Liang, et al.
Published: (2023-12-01)

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
by: Laihui Luo, et al.
Published: (2022-09-01)

Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents
by: Wang X, et al.
Published: (2023-04-01)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
by: Carlotta Antoniotti, et al.
Published: (2020-07-01)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
by: Atsushi Hiraoka, et al.
Published: (2022-02-01)